北大医药(000788) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was approximately ¥493.96 million, a decrease of 0.95% compared to ¥498.71 million in the same period last year[5]. - Net profit attributable to shareholders increased by 163.66% to approximately ¥44.05 million, up from ¥16.71 million in Q1 2023[5]. - Basic earnings per share rose by 163.93% to ¥0.0739, compared to ¥0.0280 in the same period last year[5]. - Total operating revenue for Q1 2024 was CNY 493,957,274.92, a decrease of 0.15% compared to CNY 498,709,845.17 in the previous period[21]. - Net profit for Q1 2024 was CNY 44,035,608.27, significantly up from CNY 16,693,448.90 in the same period last year, marking an increase of 163.36%[21]. - The net profit attributable to the parent company for Q1 2024 is ¥44,046,906.13, compared to ¥16,705,869.02 in Q1 2023, representing a significant increase[23]. - The basic and diluted earnings per share for Q1 2024 are both ¥0.0739, up from ¥0.0280 in the same period last year[23]. Cash Flow and Liquidity - The net cash flow from operating activities improved by 68.91%, reaching approximately -¥40.60 million, compared to -¥130.57 million in the previous year[5]. - Cash inflow from operating activities for Q1 2024 is ¥517,803,611.99, compared to ¥502,051,034.57 in Q1 2023, indicating a slight increase[24]. - The net cash flow from operating activities for Q1 2024 is -¥40,598,670.35, an improvement from -¥130,571,632.68 in Q1 2023[26]. - Total cash and cash equivalents at the end of Q1 2024 amount to ¥298,252,287.14, compared to ¥230,139,208.01 at the end of Q1 2023[26]. - Cash outflow from operating activities in Q1 2024 is ¥558,402,282.34, down from ¥632,622,667.25 in Q1 2023[26]. - The company has not reported any cash inflow from investment activities in Q1 2024, with cash outflow amounting to ¥1,676,783.60[26]. - Cash outflow from financing activities in Q1 2024 is ¥5,400,242.83, a decrease from ¥142,010,858.86 in Q1 2023[26]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥2.39 billion, a decrease of 1.78% from ¥2.44 billion at the end of the previous year[5]. - Total assets decreased to CNY 2,394,904,294.01 from CNY 2,438,286,126.08, a decline of 1.77%[20]. - Total liabilities decreased to CNY 929,457,546.61 from CNY 1,016,874,986.96, a reduction of 8.58%[20]. - The company's equity attributable to shareholders increased to CNY 1,466,104,428.37 from CNY 1,422,057,522.24, an increase of 3.1%[20]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 51,788, with no preferred shareholders[9]. - The largest shareholder, Southwest Synthetic Pharmaceutical Group Co., Ltd., holds 22.22% of the shares, with 60,107,360 shares frozen[9]. - As of the end of the reporting period, the major shareholder, Southwest Synthetic Pharmaceutical Group Co., Ltd., held 132,455,475 shares, representing a significant portion of the company's equity[10]. - The top ten shareholders include significant entities such as Southwest Synthetic Pharmaceutical Group and Beijing Medical Management, indicating concentrated ownership[10]. - The company is under the control of Xin Fangzheng Group, which also controls other related entities, suggesting potential strategic alignments[10]. Research and Development - The company's R&D expenses increased by 32.99% to approximately ¥5.06 million, reflecting ongoing project investments[7]. - Research and development expenses increased to CNY 5,061,333.88 from CNY 3,805,765.92, reflecting a growth of 32.94%[21]. Corporate Actions and Events - The company completed the deregistration of its wholly-owned subsidiary, Shanghai Fangzheng Tuokang Trading Co., Ltd., in January 2024[11]. - The company held its first temporary shareholders' meeting in 2024, where new non-independent directors and a non-employee representative supervisor were elected[12]. - The company faced a court ruling regarding a contract dispute, with all amounts owed being deducted to the court's account[14]. - The company signed a fixed asset lease agreement with Chongqing Southwest Synthetic Pharmaceutical Co., Ltd., with a lease term of three years starting from January 1, 2024[15]. Accounting and Reporting - The company has not undergone an audit for the Q1 2024 report[27]. - The company is implementing new accounting standards starting from 2024, which may affect future financial reporting[27]. - The company's financial statements for the first quarter of 2024 are pending further details[17]. Sales and Expenses - The company reported a significant reduction in sales expenses by 43.64%, totaling approximately ¥72.71 million, compared to ¥129.02 million in Q1 2023[7]. - Total operating costs decreased to CNY 442,875,679.72 from CNY 483,186,924.31, reflecting a reduction of approximately 8.35%[21]. Inventory and Receivables - Accounts receivable decreased to CNY 1,227,085,254.51 from CNY 1,247,007,169.54, a reduction of 1.6%[19]. - Inventory increased to CNY 208,699,275.27 from CNY 184,176,529.20, an increase of 13.36%[19].